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INTRODUCTION
            The burden of TB and HIV /AIDS poses unprecedented challenges on  
the public health system in India. TB and HIV are overlapping epidemics. They 
are closely   interlinked. Untreated HIV infection leads to progressive immuno 
deficiency and increased susceptibility to infections including TB. TB is the 
leading cause of HIV related morbidity and mortality.
                HIV is the most important factor fuelling the TB epidemic in 
populations with a high HIV prevalence in many countries especially in sub-
Saharan Africa1 and increasingly   in Asia and South America.
                  Studies have shown that there is close association between HIV 
and TB. Evidence of this interaction included several observations repeatedly 
made by WHO2, National governments and funding partners. 
These observations are  
• The areas that have been mostly affected by HIV epidemic also report 
the   greatest increase in the incidence and prevalence of the TB.
• The largest increase in TB cases has occurred among people aged 25- 
40 years. The very same age group mostly affected by HIV/AIDS.
• TB is the most common opportunistic infection among AIDS 
patients(Between 60-75% of AIDS patients will develop TB)
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• HIV prevalence among TB patients is higher than in the general 
population. (It is estimated a prevalence of 5.2% of HIV in adult TB 
in India).
  GLOBAL SCENERIO OF HIV AND TB
• 2 billion infected with M.Tuberculosis.
• More than 40 million are HIV infected3.       
• 15.0 million affected with HIV/TB co-infection.
• Over 90% of HIV co-infection resides in developing nations.
• 1 out of in 3 persons with HIV positive is infected with TB.
   INDIAN SCENERIO OF HIV AND TB
• India accounts for one fifth of global TB burden4.
• 40 million infected with TB bacilli.
• 1.8 million new cases of  TB occurred annually 5.
• 5.22 million are infected with HIV.
• 2 million people co-infected with TB & HIV.
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IMPACT OF HIV ON TB6
• HIV infection increases the risk of disease reactivation in people with 
latent TB. It is around 10% per year in HIV infected patients 
compared to less than 0.1 % annually in those without HIV infection.
• HIV infected patients are more susceptible to new TB infection.
• HIV is the most powerful risk factor for progression of TB infection 
to TB disease.
• Life time risk of developing TB is 60% in HIV positive as compared 
to 5-10% risk in HIV negative. 
• Increased emergence of drug resistance.
• Cause of death is complication other than TB due to accelerated 
progression of   HIV.
IMPACT OF TB ON HIV7
• TB shortens the survival of patients with HIV infection.
• TB accelerates the progression of HIV as observed 6-7 fold increase 
in HIV viral load in TB patients.
• CD4+ T cell count falls and results in  progressive immuno 
suppression.
• TB is the cause of death in 1 out of 3 people with AIDS Worldwide.
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This study is focused to know about various clinical presentations of 
tuberculosis in HIV infected patients and the relationship with CD4 count. 
As  HIV-TB  co-infection  leads  to  increased  morbidity  and  mortality 
diagnosis of HIV-TB co-infection should  be done at the earliest and thereby 
proper treatment , adequate care and support to be given all patients with 
HIV/AIDS.
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AIM OF THE STUDY
1. To study the clinical presentation of tuberculosis in HIV 
positive patients.
2. To study the correlation of CD4 count with the radiological 
findings of Pulmonary tuberculosis.
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REVIEW OF LITERATURE
HIV VIRUS
         The etiologic agent of AIDS is HIV, which belongs of family of 
human retro viruses (retro viridea) and the sub family lentiviruses. There are 
two sub types of HIV namely HIV-1and HIV-2. They are cytopathic viruses. 
HIV-1 was discovered by Luc Montagnier8 and his associates at the Institute 
Pasteur  in  Paris  in  1983.  HIV-2  was  first  identified  among  patients  in 
Cameroon  in  1985.  HIV-2  is  more  similar  to  SIV  (Simian 
Immunodeficiency Virus) than HIV-1 and it is much less virulent usually not 
resulting in full blown AIDS, but still fatal. 
The HIV variants are divided into three groups: M, for major, N, and 
O,  for  other  or  H,  I,  J,  and K.  the  B-clade  is  dominant  in  US,  Europe, 
Southeast Asia, and South America. Clades E and B are dominant in Asia 
and A, C, and D are dominant in Africa.
Morphology of HIV
Electron microscopy shows that HIV virus is an isosahedral structure 
containing  numerous  external  spikes  formed  by  the  two major  envelope 
proteins.  The  external  glycoprotein  120  and  transmembrane  glycoprotein 
141.
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 The core virus particle is composed p24 capsid protein and contains 
viral RNA and Enzymes. All retro viruses have common 3 coding regions.
• Gag - encode capsid proteins.
•  Pol  -  encode  viral  enzymes  necessary  for  replication,  reverse 
transcriptase, integrase and protease.
• Env - encode external glycoprotein that protrudes out of the lipid viral 
envelope and is responsible infectivity of the virus particles by means 
of attachment to specific cellular receptors.
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VIRAL LIFE CYCLE9
The unique feature of the virus is that it gains entry to host cells by 
binding to the CD4 receptor using the viral surface membrane glycoprotein 
120. This allows viral attachment and penetration of the host cell. The CD4 
receptor  is  present  predominantly  on  T-helper  lymphocytes,  which  are 
therefore a major target for the virus. Following penetration of the host cell, 
the viral RNA is transcribed by the viral enzyme reverse transcriptase into a 
DNA copy which becomes incorporated into the host cell genomic DNA. 
This viral DNA may then lie dormant within the cell or undergo replication 
(particularly  if  that  cell  is  stimulated)  resulting  in  transcription  of  RNA 
copies and translation to viral proteins resulting in new virus formation and 
assembly.  Viruses  then  bud  from  the  cell  surface.  New  virus  is  then 
available to infect other cells and repeat the process.
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DEFINITION OF AIDS
AIDS definition has varied widely, the most widely used the centre 
for  Disease  Control  (CDC)  classification  of  1993.  The  USA  definition 
includes individuals with CD4 count below 200/µl or CD4 percentage of 
total  lymphocyte  count  of  <14% in  addition to  the clinical  classification 
based  on  the  presence  of  specific  indicator  diagnosis  called  as  AIDS 
-defining  conditions.  In  Europe,  the  definition  remains  based  on  the 
diagnosis  of  specific  clinical  conditions  with  no  inclusion  of  CD4 
lymphocyte count.
CLASSIFICATION OF AIDS:
1993 REVISIED CLASSIFICATION SYSTEM FOR HIV INFECTION 
AND EXPANDED AIDS SURVEILLANCE CASE DEFINITION FOR 
ADULTS10
Bacterial infections, multiple or recurrent.
Candidiasis of bronchi, trachea or lungs
Candidiasis, esophageal
Cervical cancer, invasive
Coccidioidomycosis, disseminated or extrapulmonary
Cryptococosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (> 1 month's duration)
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Cytomegalovirus retinitis (with loss of vision)
Encephalopathy, HIV related
Herpes simplex, chronic ulcer (>1 month's duration) or 
bronchitis, pneumonitis or Esophagitis
Histoplasmosis, disseminated or extra pulmonary
Isosporiasis, chronic intestinal (>1 month's duration)
Kaposi sarcoma
Lymphoid  interstitial  pneumonia  and/or  pulmonary  lymphoid  hyperplasia 
Lymphoma, Burkitt's (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary of brain
Mycobacterium tuberculosis, any site (pulmonary or extra pulmonary)
Mycobaterium  avium-intracellulare  complex  or  Mycobacterium  kansasii 
(disseminated or extrapulmonary)
Pnemocystis jirovecii pneumonia
Pneumonia, recurrent
Progressive multifocal leukoencephalopathy
Salmonella septicemia,recurrent
Toxoplasmosis of brain
Wasting syndrome of HIV infection
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CLINICAL CATEGORIES
A B C
CD4+  T Cell
Categories
Asymptomatic,
acute(primary)
HIV, or PGL
Symptomatic,
Not A or C 
Conditions
 AIDS Indicator
Conditions
1.>500/uL A1 B1 C1
2.200-499/uL A2 B2 C2
3.<200/uL AIDS
indicator  T  cell 
count
A3 B3 C3
Clinical  conditions  in  category  C  are  listed  in  the  1993  aids 
Surveillance. 
CLASSIFICATION  OF  HUMAN  IMMUNODEFICIENCY  VIRUS 
INFECTION 
(WHO CLINICAL STAGING SYSTEM)
Clinical Stage 1
Asymptomatic
Persistent generalized Lymphadenopathy (PGL)
Performance scale 1; asymptomatic, normal activity
Clinical Stage 2 
Weight loss<10% of body weight
Minor mucocutaneous manifestations
Herpes zoster, within the last 5 years
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Recurrent upper respiratory tract infections (e.g. bacterial sinusitis) And/or 
performance scale 2; symptomatic, normal activity
Clinical stage 3
 Weight loss,>10% of body weight
Unexplained chronic diarrhea,> 1 month
Unexplained prolonged fever (intermittent or constant),> 1month
Oral candidiasis (thrush)
Oral hairy leukoplakia
Pulmonary tuberculosis, within the past year
Sever bacterial infections (e.g pneumonia, pyomyositis)
And/or performance scale 3; bedridden,>50% of the day during the last 
Month
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Clinical stage 4
HIV wasting syndrome
Pneumocystis jirovecii pneumonia
Toxoplasmosis of the brain
cryptosporidiosis,extrapulmonary
Cryptococcosis,extrapulmonary
Cytomegalovirus  (CMV) disease  of  an  organ other  than liver,  spleen,  or 
Lymph nodes
Herpes simplex virus (HSV) infection,mucocutaneous > 1 month,or visceral 
any duration
Progressive multifocal leukoencephalopathy (PML)
Any disseminated endemic mycosis (e.g. 
Histoplasmosis,coccidioidomycosis)
Candidiasis of the esophagus,trachea,bronchi, or lungs
Nontyphoid Salmonella septicemia
Extrapulmonary tuberculosis
Atypical mycobacteriosis, disseminated
Lymphoma
Kaposi sarcoma (KS)
HIV encephalopathy
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And/or performance scale  4:  bedridden,  >50% of the day during the last 
month.
WHO CASE DEFINITION FOR AIDS SURVEILLANCE IN ADULT 
WHERE HIV TESTING FACILITIES NOT AVAILABLE
Case definition for AIDS is fulfilled if atleast two major signs and one 
minor sign are present.
Major Signs:
• Weight loss > 10 % of body weight
• Chronic diarrhea for more than one month.
• Prolonged fever more than one month.
Minor Signs:
• Persistent cough more than one month
• History of herpes zoster
• Oropharyngeal candidiasis
• Generalised lymphadenopathy
• Chronic progressive herpes simplex infection.
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HIV – MODES OF TRANSMISSION
 I) Sexual Intercourse -84.5%  
        It  is  a  major  route  of  transmission.  The risk of  becoming infected 
depends on four major factors.
 Higher the frequencies of act, higher the number of sexual partners.
 The type of sexual act
• Anal
• Vaginal
• Oral
 The amount of viral load present in the Blood11.
 The presence of other sexually transmitted diseases or genital lesions 
in either partner.
II) Blood Borne infections 3.27% 
III) Mother to child transmission 2.16%
IV) Drug abuse 3.36%
V)  Others      6%
    HIV contaminated Instrument
 Organ transplants
 Occupational exposure
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NATURAL HISTORY OF HIV INFECTION 
The  clinical  spectrum of  HIV infection  includes  primary  infection 
(the  acute  retroviral  syndrome)  asymptomatic  infection,  early 
symptomatic infection and advanced immunodeficiency with opportunistic 
complications.   
Viral  load or  viremia  is  monitored by measurement  of  HIV-
RNA  in  plasma,  and  immunological  status  is  reflected  in  the  absolute 
number  of  CD4.  Plasma  viremia  declines  precipitously  with  antibody 
seroconversion  and  the  development  of  an  anti  HIV  immune  response 
usually reaching a steady state level within 6 to 12 months12.
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   In  most  asymptomatic  pts,  the  cd4  count  declines  gradually  over 
several years. The slope of decline is a function of the plasma viral load. 
Plasma viremia increases, accompanied by a more rapid decline in CD4 cell 
count before the onset of asymptomatic disease. As the viral load increases 
and CD4 cell count falls and risk of opportunistic infections, malignancies, 
wasting, neurologic complications and death increases substantially.
There is considerable variation in the progression of HIV disease with 
some individuals progressing from infection to AIDS in less than 5 years13 
and so called long term non progressors remaining asymptomatic without 
treatment or evidence of immunologic decline for many years14
   A number of laboratory tests have been correlated with progressive 
immunodeficiency, the development of AIDS and mortality. Taken together, 
however  the  CD4 lymphocyte  count  and  plasma  viral  load  are  the  best 
prognostic markers of the HIV infection.
  The  CD4  lymphocyte  count  a  specific  test  for  cellular  immuno 
competence is a sensitive predictor of the development of symptomatic HIV 
infection and AIDS in the near term as it reflects the current immunologic 
capacity  Conversely,  the  plasma viral  load (HIV-1RNA) is  an  extremely 
useful predictor of disease course over a more extended period of time and is 
strongly associated CD4 cell count decline.
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  In  addition  the  average  annual  decline  in  the  CD4  count  of  HIV 
infected men varied according to their initial vital load, decreasing by 36 
CD4  cells/year  among  men  with  baseline  HIV-1  RNA  less  than  500 
copies/ml and by 77 CD4 cell/year among men with baseline HIV-1 RNA 
greater than 30,000 copies/ml15.
    Put in the context of HIV pathogenesis, the viral load measures the 
replicative rate of the infection and its destructive potential for the cellular 
immune  system,  and  the  CD4  count  gauges  the  extent  of  immune 
compromise and present risk of opportunistic infections. The mean survival 
time after a CD4 count of 200/mm3   is 40 months16.
  Other  markers  of  HIV  disease  progression  include  the  HIV  p24 
antigen,  serum  b2  microglobulin,  neopterin,  and  labile  interferon  alfa, 
antip24 antibody and soluble CD8.
   Clinical  findings  may  also  predict  the  disease  progression,  oral 
candidiasis  and  oral  hairy  leucoplakia  are  early  clinical  markers  of 
immunosuppression. Generalized lymphadenopathy is also a clinical marker 
of HIV infection. Most opportunistic infection increases the risk of death 
independent of CD4 cell count17. 
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IMMUNOPATHOLOGY OF HIV INFECTION
HIV subverts  the immune system by infecting CD4+ T cells.  It  is 
clear that HIV induces dysfunction of nearly all  elements of the immune 
system and that the pathogenesis of HIV disease is multifactorial18.
CD4 was identified as the major cellular receptor for HIV fusion and 
entry in 198419. Transfection of the CD4 gene into CD-4 negative (CD-4) 
human cells rendered them infectable with HIV20.
HUMORAL IMMUNE RESPONSES
Antibodies  that  bind  HIV  proteins,  including  the  viral  surface 
envelope glycoprotein, can be detected in the plasma within weeks of HIV 
infection coincident with the decline of plasma viremia21.
Both the CD4 and co-receptor binding sites are well conserved among 
known viral isolates  and are not glycosylated. For these reasons they are 
thought to be important targets of neutralizing antibodies.
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CELLULAR IMMUNE RESPONSES
Cytotoxic T-Lymphocytes 
MHC  class  I-restricted,  HIV-specific  CD8+ cytotoxic 
T-lymphocyte (CTL) responses are found in the peripheral blood within the 
first few months of HIV infection and are detected during the chronic phase 
of infection in the majority of HIV infected individuals22.First the temporal 
association of the peak of the  HIV-specific CTL response with the decline 
of viremia during acute infections is thought to represent the effect of virus 
specific CTL in restricting HIV replication in humans23.HIV specific CD8+ T 
cells falls due to  lack of CD-4+ T-cell help.
CD-4+ T-cell Responses
Unlike  most  other  infections  of  humans,  HIV  infection  is 
characterized  by  the  absence  of  HIV  specific  CD-4+ T-cell  proliferative 
responses in the vast majority of untreated patients24.Because HIV infects 
CD-4+ T-cell, it was believed that the early loss of HIV specific proliferative 
responses may be the result of infection and deletion of HIV specific CD-4+ 
T-cell in the lymphoid tissues on encountering the virus. Thus, there is now 
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general agreement that HIV specific CD4+  T cells persist  in patients with 
progressive disease.
MECHANISMS OF CD4+ T CELL DYSFUNCTION AND 
DEPLETION25
Direct Mechanisms                                                        
 Loss of  plasma membrane integrity due to viral budding
 accumulation of unintegrated viral DNA
 Interference with cellular RNA processing
  Intracellular gp 120-CD4 autofusion events 
 Syncytia formation 
 Indirect Mechanisms
 Aberrant intracellular signalling events.
 Autoimmunity.
 Innocent bystander killing of viral antigen-coated cells.
 Apoptosis.
 Inhibition of lymphopoiesis.
 Activation induced cell death
 Elimination  of  HIV  infected  cells  by  virus-specific  immune 
response.
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RESERVOIRS OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION
RESTING CD4 T CELLS
This resting CD4 cells is established during the earliest stages of HIV 
infection.
LYMPHOID TISSUE
Lymphoid tissue is a major site of HIV replication and plays a role in 
the progression of disease throughout all stages of infection.
CD8+ T cells
Dysregulation  of  CD8+ T  cell  numbers  and  function  is  evident 
throughout the course of HIV disease. After acute primary infection, CD8+ T 
cell counts usually rebound to supernormal levels and may remain elevated 
for prolonged periods. Increase in CD8+ T cells during all but the late stages 
of disease may in part reflect the expansion of HIV specific CD8+ cytotoxic 
T lymphocytes. In addition to cytotoxic T lymphocyte activity, other CD8+ T 
cell functions are impaired during HIV disease progression, including loss of 
noncytolytic non-MHC restricted CD8+ T cell derived HIV suppression
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B-lymphocytes:
Dysregulation of B -cell activation and the decreased ability of these 
cells to respond to antigen are likely responsible in part for the increase in 
certain bacterial infections seen in advanced HIV disease in adults.
NATURAL KILLER CELLS 
Abnormalities of NK cells are observed throughout the course of HIV 
disease and these abnormalities increase progression. NK cells, like CD8+ T 
cells,  may inhibit  HIV replication by cell-mediated killing, as well as by 
secretion of soluble HIV inhibitory factors.
NEUTROPHILS 
Dysregulation  of  neutrophil  function  occurs  at  all  stages  of  HIV 
infection.  The  oxidative  capacity  of  neutrophils  after  priming  with 
granulocyte macrophage colony-stimulating factor is also increased in HIV 
infected individuals. The opsonizing activity of neutrophils is significantly 
impaired  in  HIV infection  and the  degree  of  impairment  correlated  with 
disease progression.
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MONOCYTE – MACROPHAGES
Cells  of  the  monocyte-macrophage  lineage  play  key  roles  in  the 
immunopathogenesis of HIV disease. Dysfunction of these cells contributes 
to CD4+  T cells dysfunction and to impair host defense against intracellular 
pathogens.  These  cells  are  central  to  the  pathogenesis  of  HIV-induced 
central nervous system disease.
DENDRITIC CELLS
Dendritic  cells  are  among  the  first  cells  to  encounter  HIV  after 
mucosal26 exposure and are probably responsible for transporting the virus to 
lymphoid  organs  thus  facilitating  infection  of  CD4+  T  cells  and  viral 
dissemination.
TUBERCULOSIS
 Magnitude of Tuberculosis in India
• Today 2 of every 5 Indians are infected with TB bacilli. There is a 
strong chance of that of them atleast 10 % will develop TB disease.
• 1.8 million new TB cases occurred annually
• Among that 0.8 millions have sputum positive.
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• 1 sputum positive patient can infect 10 to 15 persons in a year if left 
untreated.
The  etiologic  agent  of  Tuberculosis  in  human  is  Mycobacterium 
tuberculosis. It is a rod shaped, non spore forming thin aerobic bacterium, 
measuring  0.5  µm  to  3  µm.  they  are  often  neutral  on  gram's  staining 
.However, once stained, the bacilli cannot be decolorized by acid alcohol. 
Acid fastness is due to high content of mycolic acids, long chain cross linked 
fatty acids, and other cell wall lipids.
Mode of transmission
   M.Tuberculosis  most  commonly  transmitted  from  a  patient  with 
infectious pulmonary Tuberculosis to other persons by droplet nuclei, which 
are aerosolized by coughing,  sneezing or speaking.  The tiny droplets dry 
rapidly. The smallest (<10µm in diameter) may remain suspended in the air 
for several hours and may gain direct access to the terminal  air  passages 
when inhaled.
Determinants of transmission of infection from exposure 
     Depends on
• Intimacy and duration of that contact.
• The degree of infectiousness of the case.
• The shared environment of the contact, such as over crowding in poor 
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ventilated rooms.
• Cases with sputum AFB positive by microscopy are highly infectious.
Determination of development of disease from infections
Depends on:
• Endogenous  factors,  such  as  individual  innate  susceptibility  to 
disease and level of functions of cell mediated immunity.
• Age is an important determinant of the risk of disease after infectious. 
Among  infected  persons,  the  highest  during  late  adolescence  and 
early adulthood. The incidence of women peaks at 25 to 34 years of 
age. The risk may increase in elderly, because of waning immunity 
and co-morbidity.
• The presence of HIV co-morbidity.
Pathogenesis and immunity
About  2  to  4  weeks  after  infection,  two  host  responses  to 
M.Tuberculosis  develop:  a  tissue  damaging  response  and  a  macrophage-
activating response. The tissue damaging response is the result of a delayed 
-type  hypersensitivity  (DTH)  reaction  to  various  bacillary  antigens;  it 
destroys  non-activated  macrophages  that  contain  multiplying  bacilli.  The 
macrophage-activating response is a cell mediated phenomenon resulting in 
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the  activation  of  macrophages  that  are  capable  of  killing  and  digesting 
tubercle bacilli. 
Although both of these responses can inhibit mycobacterial growth, it 
is the balance between the two that determines the form of tuberculosis that 
will  develop  subsequently.  Cell  mediated  immunity  confers  partial 
protection against M.tuberculosis, while humoral immunity has no defined 
role in protection. 
2  types  of  cells  are  essential.  Macrophages,  which  directly 
phagocytize tubercle bacilli and T cells (mainly CD4+ lymphocytes) which 
induce  protection  through  the  production  of  lymphokines  especially 
interferon γ (IFN- γ) alveolar macrophages secrete a number of cytokines.
• Interleukin 1 (IL-I) contributes to fever 
• Interleukin  (IL-6) contributes to hyperglobulinimea
• Tumor  necrosis  factor  α  (TNF  α)  contributes  to  killing  of 
mycobacteria the formation of granulomas. Systemic effects such as 
fever and weight loss.
      Reactive CD4+ lymphocytes produces cytokines of the TH-1 pattern 
and  participate  in  MHC  class  II  restricted  killing  of  cells  infected  with 
M.Tuberculosis.  TH I CD4+ produces IFN- γ and IL-2 and promotes cell 
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mediated  immunity.  TH-2  cells  produce  IL-4,  IL-5,  IL-10  and  promote 
humoral immunity.
CLINICAL MANIFESTATIONS
Tuberculosis  is classified as pulmonary or extra-pulmonary.  Before 
the  recognition  of  HIV infection,>80% of  all  cases  of  tuberculosis  were 
limited to the lungs. However, up to two-thirds of HIV infected patients with 
tuberculosis  may  have  both  pulmonary  and  extrapulmonary  disease  and 
extrapulmonary disease alone. Pulmonary tuberculosis: It can be primary or 
post primary (secondary).
Primary disease
Droplet nuclei, which are inhaled into the lungs, lodge in the terminal 
alveoli of the lungs. The resulting lesion is Ghon focus. Lymphatics drain 
the  bacilli  to  hilar  lymphnodes.  The  Ghon  focus  and  related  hilar 
lymphadenopathy  form  the  primary  complex.  The  immune  response 
develops about 4 to 6 weeks after primary infection. 
The  size  of  infecting  dose  of  bacilli  and  the  strength  of  immune 
response determine subsequent course. In most cases the immune response 
stops the multiplication of bacilli. However a few dormant bacilli persist. If 
the immune response is not strong enough to prevent multiplication bacilli, 
the disease occurs within a few months.
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Outcome of primary infection:
Primary
complex
No clinical disease
Positive tuberculin skin test
Usual Outcome: 90% cases 
Hypersensitivity reactions
e.g. Erythema Nodosum
       Phlyctenular Conjunctivitis
       Dactylitis
Pulmonary & Pleural complications
e.g.  Tuberculous Pneumonia
        Hyperinflation and collapse/consolidation
        Pleural effusion
Disseminated disease
Lymphedenopathy
Meningitis,Pericarditis
Miliary disease
33
Post primary Tuberculosis
• Post  primary  also  called  adult  type,  reactivation  or  secondary 
tuberculosis
• Due to endogenous reactivation of latent infection.
• Usually localized to the apical and posterior segments of upper lobes, 
where  the  high  oxygen  concentration  favor  myco  bacterial  growth 
Superior segments of the lower lobe also frequently affected.
• May present  as cavities,  upper lobe infiltrates,  fibrosis,  progressive 
pneumonia, endobronchial TB.
Symptoms and signs
General symptoms are like fever, night sweats, weight loss, anorexia, 
malaise and general weakness.  Respiratory symptoms are cough, purulent 
sputum, hemoptysis, dysnoea pleuritic chest pain and wheeze.
Physical  findings  are  of  limited  value  in  pulmonary  tuberculosis. 
Crepitations  are  present  and  persist  during  inspiration  especially  after 
coughing, rhonchi due to partial obstruction of bronchi, and amphoric breath 
sounds in cases with large cavities in the lung.
Systemic  features  include  fever  (low  grade  and  intermittent)  and 
wasting pallor and clubbing may occur in chronic tuberculosis. Anemea and 
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leukocytosis  can  occur.  Hyponatremia  due  to  the  syndrome  of 
innappropriate anti diuretic hormone (SIADH) can occur.
Extra pulmonary Tuberculosis
In the order of frequency, sites to be involved are lymphnodes, pleura, 
genitourinary tract, bone and joints, meninges, peritoneum, and pericardium. 
As  a  result  of  heamatogenous  spread  extrapulmonary  TB  is  seen  more 
commonly today.
Tuberculosis lymphadenitis
 It is the most common presentation of extra pulmonary tuberculosis in 
HIV infected patients.   Most commonly cervical and supraclavicular sites 
are  involved.  Diagnosed  by  fine  needle  aspiration  cytology  or  surgical 
biopsy. AFB are seen in 50% of  cases, cultures are positive in 70 to 80% 
and  histologic  examination  shows   granulomatous  lesion.  Among  HIV 
infected patients, granulomatous disease is  usually not seen.
Miliary or disseminated tuberculosis
• Due to heamatogenous spread of TB bacilli.
• In children it is due to recent primary infections.
• In adults due to the recent infection or reactivation of old dormant 
foci.
• Lesions  are  1-2  mm  in  diameter  resemble  millet  seeds  Physical 
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findings include hepatosplenomegely, lymphadenopathy, eye-choroid 
tubercle  seen  upto  30%  case.  Meningismus  can  occur,  chest 
radiography  shows  miliary  reticulonodular  pattern,  other  findings 
include large interstitial infiltrates and pleural effusion.
DIAGNOSIS
1. AFB Microscopy 
Samples are sputum, tissue, urine, gastric lavage. 
Sputum  microscopy27  -  three  specimens  are  currently  recommended  by 
WHO  for  ruling  out  pulmonary  tuberculosis.  The  rationale  behind  this 
recommendation is that some patients shed mycobacteria irregularly and in 
small numbers; thus increasing the number of specimens would increase the 
yield. The chance of missing positive cases on smear is reduced if more than 
one specimen is examined; the first spot specimen has a case yield of 86 to 
90%. The second sputum sample examination takes the yield to over 98%. 
The overall yield for smears is superior with multiple specimens than with a 
single specimen28.   
2. Microbacterial culture - Using (Lowenstein-Jensen or Middlebrook 7H10) 
and incubated at 37 c under      5% co2. Bacilli grow slowlyand requires  4-8 
weeks.  Rapid diagnosis is possible within 2 to 6 days by Bactec method 
using radio metric culture system.
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3. Chest x-ray   
A characteristic feature which favors the diagnosis of TB29 is 
• Opacities mainly the upper zone.
• Patchy or nodular opacities.
• Cavitating lesions.
• Presence of calcification.
       Normal chest film, although not completely, not exclude pulmonary 
tuberculosis.                                          
4. PPD skin testing
        It is widely used in screening for M.Tuberculosis. Limited value in 
active tuberculosis because of low sensitivity and specificity. 
5. Nucleic acid amplification (NAA) Test30, 31
   There  are  2  direct  amplification  tests  to  detect  Mycobacterium 
tuberculosis from clinical specimens. At this point of time it is important to 
note  that  the  US  FDA  has  only  validated  these  tests  for  respiratory 
specimens. Approval of NAA tests on blood is still awaited.
a)  DNA tests
    Polymerase Chain reaction.  In this test, a segment of the DNA is 
amplified and the finished products run on a gel to look for bands. This is a 
qualitative test.
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     A recent  addition  to  the  PCR range is  the  Real  time  PCR,  which 
actually  gives  a  quantitative  estimation  of  the  number  of  DNA  copies 
present in the sample.
b) RNA tests
Transcription mediated amplification: It is better than DNA PCR.
          These NAA test results should be interpreted with caution because of 
the possibilities of false positives and false negatives and the reliability of 
the lab performing the test. 
6. Cytokine release assay-QuantiFERON-TB test. 
It  is  useful  for  the  diagnosis  of  latent  tuberculous  infection  useful 
particularly in HIV infected patients and children.
Additional diagnostic procedures
• sputum induction by ultrasonic nebulisation of hypertonic saline
• fibreoptic  bronchoscopy  with  bronchial  washings  or  transbronchial 
biopsy
• Bronchoalveolar lavage
• Invasive procedures for suspected extrapulmonary TB like CSF for 
TBM,pleural fluid and biopsy for pleural effusion,bone marrow and 
liver biopsy for miliary TB.
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HIV & TB CO-INFECTION
HIV infected patients are at markedly increased risk for reactivation 
TB and for second episode of Tuberculosis from exogenous reinfection. The 
suggested  mechanism  of  reactivation  or  increase  in  susceptibility  of  TB 
infections in HIV positive patients are due to depletion of CD4 lymphocytes 
and macrophages.
IMMUNE INTERACTION IN HIV AND TUBERCULOSIS32
The  key  components  of  the  immune  response  in  TB  include  T 
Lymphocytes and alveolar macrophages.CD4+ T Lymphocytes, especially 
the  T-helper  type  1  (Th1)  subclass,  are  the  major  effector  cell  in  cell-
mediated immunity of TB or the ‘policeman’ responsible for controlling TB. 
When M. Tuberculosis reaches the lower respiratory tract, the initial defence 
against infection is alveolar macrophage. The organism is engulfed by the 
macrophage through  phagocytosis. Subsequently,  macrophage lymphocyte 
interaction involves Th-1 and natural killer lymphocytes that secrete  IFN-
alpha  in  response  to  mycobacterial  antigens,  which  activates  alveolar 
macrophage to produce a variety of mediators including reactive oxygen and 
nitrogen  species  that  are  involved  in  growth  inhibition  and  killing  of 
mycobacteria.  These cellular interactions are mediated by Th-1 cytokines. 
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Macrophages can also secrete interleukin (IL)-12,another Th-1 cytokine, in a 
positive feedback loop to amplify this process.
                 In HIV, CD4+ T  cell depletion removes policeman of TB  control 
in  the  lung  resulting  in  dissemination  of  Mycobacterium  tuberculosis. 
Consequently,  disseminated  tuberculosis  (DTB)  and  extrapulmonary 
tuberculosis  (EPTB) are more common.  On the other  hand, the activated 
macrophages also release proinflammatory cytokines, such as tumor necrosis 
factor- alfa, IL-1 and IL -6 which enhance HIV replication and thus HIV 
load.
      The risk of death in HIV infected patients with TB was reported to be 
twice that in HIV infected patients without TB independently of the CD4 
cell count. The higher mortality rate among patients with TB appeared to be 
due to progressive HIV infection rather than TB.
PATHOLOGY
A wide spectrum of histopathological changes33 is seen in HIV infected 
patients with TB. However, there are three identifiable histological stages of 
cellular immune responses which may also correlate with the stage of HIV 
infection.
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A. Granulomatous response 
  Relatively  intact  cellular  immune  response  and  have  typical 
granulomatous response.
 Epitheloid macrophage and langerhan’s giant cell abundantly present.
 Number of myco bactria in lesion are reduced.
 Cluster of CD4+ T-cell around epitheloid macrophage.
   B. HYPOREACTIVE RESPONSE
      With progressive immune suppresion and decrease in CD4+ T-cell 
count,
 loss of Epitheloid macrophage and langhans giant cell. 
 number of  myco bactria in lesion are increased.
 necrosis in mixed suppurative and caseous lesions.
C.  ANERGIC RESPONSE
        In late stage of AIDS, no relative decrease in no of macrophages 
 langhans giant cell  are absent.
 granuloma formation absent.
 caseous  necrosis  is  replaced  suppuration,  coagulative  necrosis  and 
apoptotic debris seen.
 Large no of myco bacteria are present with in macrophages.
41
CLINICAL PRESENTATON OF HIV –TB COINFECTION34, 35,36
The  clinical  features  of  Tuberculosis  in  HIV  patients  depends  on 
whether TB occurs in early or late in the course of HIV .The presentation 
depends on the degree of immunosuppression.  Weight loss and fever are 
more common in HIV positive with TB. Patients than in those who are HIV 
negative.  Conversely,  cough  and  hemoptysis  are  less  common  in  HIV 
positive pulmonary TB, because there is less cavitation / inflammation and 
endobronchial irritation in HIV positive patients. When TB tends to occur 
earlier in the course HIV infection, the clinical, radiological, bacteriological 
findings do not defer substantially from those HIV negative patients. Thus 
there  is  predominantly  pulmonary  lesions  located  at  the  upper  lobe  and 
cavitation results. Tuberculin test are positive and sputum smear positivity is 
not reduced.
     When TB occurs late in the course of HIV infection or in patients 
with AIDS, the features are more atypical. Pulmonary disease may occur in 
atypical  sites  such  as  lower  zone  or  diffuse  consolidation.  Mediastinal 
adenopathy is more common and involvement of extra pulmonary sites such 
as  lymphnodes,  brain,  pleura,  pericardium,  bone,  GIT.   In  chest  X-ray 
diffuse  lower  lobe  reticulo  nodular  infiltrates  and  mediastinal/hilar 
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adenopathy are more common. Tuberculin positivity is less common.Sputum 
smear negative is more common.   
Feature of PTB
                    Stage of HIV infection
Early Late
Clinical picture Often  resembles,post 
primary PTB
Often resembles,primary
PTB
Sputum smear positive Often negative
Chest x-ray Often cavitating Often 
infltrating,intrathoracic 
adenopathy,no cavitation
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Diagnosis of TB in HIV infection
The diagnosis of tuberculosis in HIV infected patients may be difficult not 
only because of the increased frequency of sputum-smear negativity ( up to 
40% in culture-proven pulmonary cases) but also because of 
 atypical radiographic findings
 a lack of classic granuloma formation in the late stages
 negative results in PPD skin tests.
Diagnostic difficulties
Patients with HIV have frequent pulmonary infection .Each time such 
as infection occurs , the patient must be evaluated for TB .The causes of 
respiratory infection in HIV  which  gives confusion with pulmonary TB 
include bacterial   pnenumonia  ,  pneumocystitis  carinii  ,  suppurative lung 
disease,  myco  bacterium  avium  complex,  cytomegalovirus  virus,  fungal 
infections.  Myco bacterium TB infection develops when the CD4+ count 
falls below 400/ml as compare to other infection which develop when the 
CD4+ falls much below 250/ml.  In general,  Tuberculosis  develops under 
any  CD4+  value  but,  if  the  count  go  below  200/ml  a  more  atypical 
presentation of pulmonary TB often occurs.
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MANAGEMENT OF HIV-TB CO INFECTION36, 37
 
The  treatment  tuberculosis  and  HIV  Co  infection  presents  with 
significant challenges due to concerns of drug-drug interactions, toxicities, 
added pill burden and adherence issues.
The  management  of  TB/HIV  infection  should  follow  the  same 
principles  as  for  persons  without  HIV  infection  except  for  the  use  of 
Thiacetazone. (Thiacetazone causes severe cutaneous reactions, exfoliative 
dermatitis  and even Steven Johnson Syndrome.  Ethambutol  may be used 
instead of thiacetazone). The regimen should consist of the standard 4 drug 
therapy,  as  per  TB  treatment  guidelines,  that  is,  INH,  Rifampin, 
pyrazinamide, ethambutol or streptomycin given for 2 months followed by 
INH and RIF for 4 months when the organisms are sensitive to first line 
agents. In the event of a slow or suboptimal response, prolongation of the 
continuation phase to 7 months should be considered. Intermittent therapy 
should be avoided.
CHEMOPROPHYLAXIS
   HIV  infected  patients,  are  at  high  risk  for  progressive  TB  and 
therefore  after  active  TB,  has  been  ruled  out,  it  is  important  to  give 
prophylaxis to patients with a PPD induration of. 5mm, previous positive 
PPD or those who have been in close contact with a case of pulmonary TB. 
This can be given as 6-12 months of daily or twice weekly INH + either 
rifampicin or rifabutin with comparable efficacy.
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RECOMMENDATIONS38
 Treatment  principles  +  for  HIV  +ve  and  HIV  –ve  individuals 
remain the same.
 Patients of active TB require immediate treatment.
 In ART naïve patients, wait for 4-8 weeks after starting AKT and 
then begin antiretroviral treatment. This aids the clinician in better 
judgment of side effects and paradoxical reactions.
 EFV based regimens should be preferred.
 Directly observed therapy is better for HIV-TB coinfected patients.
 Though the potential for drug interaction between Rifamycins and 
antiretroviral  agents  is  high,  rifampin  should be included in the 
regimens with dose adjustments.
 Rifamycins may become resistant with intermittent therapy.
 There  may  be  paradoxical  reactions  or  immune  reconstitution 
syndrome (IRS) during treatment with ATT the may be interpreted 
as  clinical  worsening.  These  will  mimic  worsening  of  the 
tuberculosis  and  are  characterized  by  fever,  new  infiltrates,  or 
increasing pleural effusion. such patients should be continued with 
the ATT and Antiretrovial treatment 
 (ATT) along with NSAIDS and high dose Prednisone (1mg/kg * 1-
2 weeks, followed by tapering doses) in severe cases.
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Situation Recommendations
Pulmonary  TB  and 
CD4+<50/cumm  or  extra 
pulmonary TB
Start Tb therapy followed by ATT soon as 
the patient tolerates ATT drugs. Watch for 
development of IRS
Pulmonary  TB  and  CD4  50-
200/cumm  or  total 
lymphocytic  count<1000-
1200/cumm
Start  Tb  therapy.  Start  one  of  these 
regimens  as  soon  as  patient  is  able  to 
tolerate ATT and is clinically stable. Delay 
in starting ART may increase risk to other 
OIs.
PTB  and  CD4>200cumm  or 
total  lymphocytic  count 
>1000-1200/cumm.
Treat TB. Monitor CD4 counts. Start ART 
after completion of ATT.
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MATERIALS AND METHODS
Place of Study : Department of Medicine, KMCH
Type of Study : Cross sectional Study
Collaborating Department : Chest Clinic, ART Clinic
Duration of Study : January 2006 to July 2007
CASE SELECTION
INCLUSION CRITERIA
• Patients who have been diagnosed as HIV positive   either by Rapid 
Test or ELISA and who have clinical and investigatory evidence of 
pulmonary TB or Extra pulmonary TB are enrolled in the study. These 
patients are picked up from ART Clinic.
• Those  patients  who  sought  medical  attention  for  any  form  of 
Tuberculosis at chest clinic OP, who are HIV negative, are chosen as 
controls.
• Patients between the age group of 15 to 55 are enrolled in the study.
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EXCLUSION CRITERIA
• Patients below the age of 15 and above the age of 55 are excluded in 
the study.
• HIV positive individuals who did not have clinical or investigatory 
evidence of any form of TB were excluded. 
• Patients  who  had  other  causes  of  immuno  suppression  such  as 
Diabetes, Lymphoma, Leukemea, visceral malignancy, malnutrition, 
on immuno suppressive drugs were excluded.
METHODOLOGY
CLINICAL EXAMINATION 
All HIV positive patients  were  meticulously  examined for  the 
presence of Pulmonary and Extra pulmonary Tuberculosis.  Their symptoms 
were analyzed in a detailed manner.  Complete  general  examinations   for 
presence of opportunistic infection and respiratory system and other system 
examination were done. 
      All of them were subjected to the following investigations. Basic 
blood  investigation,  sputum smear  for  AFB,  chest  x-ray  PA  view,  PPD 
reactivity by mantaoux test and CD4 count. Special investigations were done 
in patients with extra pulmonary TB like FNAC of lymphnode, biopsy, and 
CSF analysis. 
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1. SPUTUM SMEAR FOR AFB  
Done by using Ziehl Neelsen technique:
• Fix the smear on the slide
• Cover the fixed smear with carbol fuchsin for 3 minutes
• Heat, rinse with tap water and decolorize with acid alcholol for 3 
-5 seconds.
• Counterstain with methylene blue for 3 – 5 seconds.
• Rinse again with tap water.
• Observe under microscope by using the oil immersion lens.
The bacilli appears as red, beeded rods, 2- 5 µm long and 0.25 – 0.5 µm 
wide.
Minimum of three sputum samples (2 spot + 1 early morning sample) should 
be examined.
Results are read as follows.
If the slide has Results Positive (grading)
More than 10 AFB per oil immersion field Pos 3+
1-10 AFB per oil immersion field Pos 2+
10-99 AFB per 100 oil immersion fields Pos 1+
1-9 AFB per 100 oil immersion fields scanty Record exact figure
NO AFB in 100 oil immersion fields Neg -
In cases of TB Lymphadenitis, FNAC of the lymphnode was done.
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2. Chest Skiagram
All patients were taken x-ray chest PA views and if necessary lateral 
view.  Infiltrations  are  carefully  looked  and  also  looked  for  cavitation, 
lymphnode enlargement either in the mediastinum and/or hilar region.
3. PPD Reactivity by Mantaux 
 0.1 ml of purified protein derivative – 5TU injected intra dermally 
into the left forearm of the patients. The results are read at 48-72 hours later. 
In duration in the transverse axis is measured. Positive reactions indicate that 
the patients had been exposed to TB bacilli. In duration of more than 5 mm 
is indicative of TB infection in HIV infected patients.
4. CSF ANALYSIS
     
In patients who had presented with signs of meningeal  irritation or 
altered sensorium lumbar puncture was performed under aseptic precautions. 
CSF was  subjected  to  cytology and  bio  chemical  analysis.  CSF analysis 
favoured TB meningitis 
5. CD4 count assay
       
     Blood  was  collected  in  heparinized  bottles  for  flow  cytometry 
analysis. Blood was drawn in the morning and heparinized and was sent to 
Chennai Medical College for analysis of CD3, CD4 and CD8 counts by flow 
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cytometry. Flow cytometry is used in the phenotyping of T cell subsets for 
monitoring of HIV pts39.
PROCEDURE
       The  Heparinized  blood  of  about  100  µl  of  whole  blood  is 
simultaneously stained and analyzed for CD3, CD4 AND CD8 by FACS 
Count Cytometry using LASER40.
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RESULTS AND OBSERVATION
A total number of 60 patients of HIV +ve TB and 30 patients HIV-ve 
TB were enrolled in this study. All the data were fed into a computer and the 
results were collected using an epidemiology incorporated software.
The following test statistics were used
1) two sample t test
2) wilcoxon Rank Sum test/Mann -Whitney test
3)  Chi-square test
4)  Fisher -exact 
53
DISCUSSION
TB is the most common opportunistic infection in HIV/AIDS patients 
41,42,43   TB and HIV  fuel each other, hence untreated HIV - TB co infection 
further  increases   the  morbidity  and mortality  in  HIV/AIDS patients.  So 
early diagnosis is very necessary  to prevent the morbidity and mortality.
This study documents the various clinical presentations of TB among 
HIV and non HIV patients.  The x-ray presentation,sputum AFB,mantoux 
reactivity were analysed in  both these groups . CD4  count was analysed in 
HIV patients   and compared with  radiological presentations.
     The observations made in these studies  that males were commonly 
infected when compared to females .The mean age group for male 35.95 and 
female 28.84 in the HIV group and mean age group for male is 33.78 and 
female is 27.71 in non HIV TB group.
      
     Out of 60 cases of HIV - TB, 45 cases are pulmonary TB,15 cases are 
extra  pulmonary TB and among 30 cases  of non HIV-TB ,  26 cases are 
pulmonary TB, 4 cases are extra pulmonary TB . There is no significant 
correlation. But various studies show that even in HIV/AIDS  pulmonary TB 
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is the most common. It  basically depends on  the level of patients immuno 
suppression.   When  TB  occurs  in  the  earlier  period  of  HIV 
infection,pulmonary  TB is  more  common.   When  TB occurs  late  in  the 
period HIV infection, i.e after a significantly depressed CD4 count, extra 
pulmonary  TB  is  more  common.  Sometimes  both  pulmonary  and  extra 
pulmonary TB may co-exist in the same patient.
   On analyzing the extra pulmonary  TB ,out of 15 cases, 7 cases are TB 
Lymphadenitis , 5 cases are pleural effusuion, 1 is TBM,1 is GIT, 1 is bone. 
The various studies44,45   also document the site of EPTB  are in the same 
order  of  occurence  like  lymphnode,  pleura  ,pericardium,  meninges,  GIT, 
GUT,  bone  and  others.   Dr.  Fitz  Gerald,  Dr.  Stan  et  al  University  of 
Coloumbia46  have noted these points.
   On  analyzing  symptomatology  of  pulmonary  TB,  almost  all  the 
cardinal symptoms are present in both the groups, but fever and weight loss 
are the commonest presenting symptoms of HIV-TB i.e about 88% and 91 % 
respectively. Whereas, cough with expectoration and hemoptysis are more 
common in non HIV - TB group i.e about 80%. and 46%. Hemoptysis is 
present  only  in  6%  present  in  HIV  group.  This  symptom  analysis  has 
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significant ‘p’ value Dyspnoea, chest pain have no significant  differences in 
presentation in  both groups .The reason being cough and hemoptysis are 
less  common  in  HIV  group  is  due  to  less  cavitation  and  less  bronchial 
irritation.  One  study  conducted  by  Dr.  Sowmya  Swaminathan,
Dr. Rajasekaran, Dr. S. Sangeetha et al, TRC, Chennai also stated the same 
point.47,48
        
There are interesting observations on made in the x-ray chest. In HIV 
TB the  most common x-ray presentation are mediastinal adenopathy, lower 
zone  infiltration,  combined,  bilateral  extensive  infiltration,  and  millary 
mottling .  Out of 45 cases, 16 cases are found to be mediastinal adenopathy 
whereas no cases of mediastinal adenopathy was found in non HIV group. 
The  ‘P’ value  is 0.00020 which is significant.
             Lower zone infiltraion was 10 out of 45 patients in HIV - TB group 
whereas 1 case was found in non HIV-TB .The ‘P’ value is 0.03636 which is 
significant.  Various other studies also shown this atypical  presentation in 
high percentage.  This  is  very much consistent  with observation made by 
Zumla Malon and Henderson et  al49.  They have found 50 % of case are 
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having  mediastinal  adenopathy  similar  observation  also  documented  by 
Dianev Havlir, Peter F. Branes M.D. et al.
        Another interesting finding in these studies are absence of cavitaiton in 
HIV TB whereas 58 % are cavitating in non HIV group. The ‘P’ value is 
0.00 which is significant. This finding was consistent with observation made 
by Decker CF and Lazarus A et al. mentioned in that post graduate medical 
journal 2000.Upper lobe cavitating lesion is not common is noted by several 
other authors also and including Zumla Malon and Henderson et al. 49
           There is 1 case of miliary mottling in HIV whereas no millary 
mottling  in  non  HIV.  The  ‘p’  value  is  0.6338  which  is  not  significant.
Dr. Sowmya Swaminathan et al TRC has noted 11 cases out of 78 HIV-TB. 
This incidence is quite higher than made in the study.
               3 cases are normal chest x-ray in spite of sputum AFB positivity in 
HIV/TB group.This  normal  ches  x-ray  in  HIV patient  is  also  noted   by 
Dianev Havlir, Peter F.Branes M.D. et al  50.  Ideally all HIV patient with 
normal chest x-ray should be subjected to HRCT  thorax because the finding 
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of low density lymphnode with peripheral enhancement on a contrast CT is 
highly predictive  of tuberclosis.
        
             On analyzing the radiographic pattern with CD4 count, it is very 
well noted  when the count >200 upper zone infiltration is common. When 
the count is <200 atypical presentation like mediastinal adenopathy, lower 
zone infiltration are common. This has significant ‘P’ value. Various studies 
also proved this statement.51,52,53
       Regarding sputum AFB analysis, 13 out of 60 cases in HIV-TB, 20 
out of 30 in non HIV-TB are smear positive for AFB. The ‘P’ value 0.00001 
which is quite significant .This is consistent with observation made out by 
Zumla  Malon and Henderson et  al  .The reason being less  sputum smear 
positivity  in  HIV/TB  is  due  to  less  cavity  formation.  Sputum  smear 
negativity alone does not indicate absence of tuberculous infection. Ideally54 
these patients should be subjected to sputum culture and sensitivity. Even 
more  this  bronchoscopy,  BAL,  Transbronchial  biopsy  may  be  needed  to 
prove semar positivity.
   Regarding PPD reactivity by mantoux  test  the mean Induration in 
HIV-TB patients are  2.9 mm whereas non HIV-TB, mean induration are 
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12.8 mm. The ‘p’ value 0.00 which is quite significant . Zumla Malon and 
Henderson et al also insisted negative TB are more common in HIV positive 
individuals. Mark FitzGerald, MD and Stan Houston, MD et al observed in 
his study and stated the false negative tuberculosis test are more likely in a 
HIV infected  patients  and  is  increasingly  more  common  with  increasing 
immuno  suppression.   Kothari  et  al55  stated  that  on  induration  5mm 
following injection of  tuberculin is  taken as positive test  for  TB in HIV 
infected individuals.
              On analysing CD4 count the mean CD4 count of 45 out of 60 cases 
of pulmonary HIV-TB is 174.2 whereas the mean CD4 15 out of 60 cases of 
extra pulmonary HIV-TB 114.6 .The ‘p’ value is 0.0285 which is significant. 
This is consistent with the observation made out of Post FA,Wood R ,Pillay 
GP et al56. in South Africa and various other authors also.
          Infact  Tuberculosis can develop at  any CD4 count.  If the CD4 count 
is moderately low pulmonary Tuberculosis is common. But when the CD4 
count is very much lowered extra pulmonary tuberculosis is more common 
than  pulmonary  TB.  Moreover  atypical  myco  bacterial  lesions  and 
opportunistic infections are common.
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CONCLUSION
1. 1.As  TB is the most  common opportunistic infection  in all HIV 
positive    individuals, hence all HIV patients should be screened 
for TB and all TB patients should be screened for HIV status.  
2. Tuberculosis has multiple  clinical presentations in patients with 
HIV infection.        
3. Atypical chest x-ray findings are common in HIV-TB co infection. 
4. The  most  common  atypical  presentations  are  mediastinal 
adenopathy, lower zone infiltration and   miliary mottling.
5. Cavitation is  rare in HIV-TB co infection.
6. When the CD4 count is more than 200, upper zone infiltration is 
more    common. When the CD4 count   less than 200 atypical x-
ray findings are common.
7. Sputum smear negativity is more common,hence sputum culture is 
essential as a screening procedure .
8. Mantoux test often is false negative in HIV-TB co infection.
9. Lymphnodes, meninges and pleura are the common sites of extra 
pulmonary TB involvement.
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10.Tuberculosis can occur at any level of depletions of CD4 count but 
when the CD4 count level is grossly low extra pulmonary  TB is 
more common.
Since TB-HIV fuel each other, early diagnosis and proper effective 
management are essential to reduce the morbidity and mortality.
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A STUDY ON THE CLINICAL PRESENTATION OF
PROFORMA
Name Socioeconomic Status
Age Height
Sex Weight
Address
Hospital No
HISTORY
Yes No
Constitutional Symptoms   
Cough with Expectoration   
Fever   
Loss of 
Weight   
Hemoptysis   
Chest Pain   
Breathlessness   
Others (if any)   
Past History of Tuberculosis Yes No
  
Family History of Tuberculosis Yes No
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      General Examination
Examination of Respiratory System
Inspection Palpation Percussion Auscultation
  
 
 
Clinical 
Diagnosis:
INVESTIGATIONS
Sputum AFB Positive Negative
  
Upper Zone Mid zone
Lower 
Zone Extensive
Chest X-Ray    
Unilateral Bilateral
  
Nodular Fluffy
  
Mantoux Test 0-5 mm 5-10 mm > 10 mm
  
A
Others (if any),
CD 4 count < 200 > 200
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ABBREVIATIONS
1. AIDS           Acquired Immuno deficiency Syndrome.
2.  HIV            Human immuno deficiency Virus.
3.  PTB            Pulmonary Tuberculosis.
4.  EPTB          Extra Pulmonary Tuberculosis
5.  CD4             Cluster of differentiation
6.  DNA            Deoxy Ribonucleic Acid
7.  RNA            Ribonucleic Acid
8.  PPD             Purified Protein Derivative
9.  IL                 Interleukin
10. IFN              Interferon
11. PCR              Polymerase chain reaction
12. ART             Anti Retroviral treatment
13. OI                 Opportunistic infection
14. IRS                Immune Reconstitution Syndrome.
15. HRCT           High Resoultion computerized Tomogram.
16. BAL              Bronchoalveolar  Lavage.
17. AFB              Acid Fast Bacilli
18. FNAC         Fine needle aspiration cytology
19. MHC         Major histo compatability complex
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